Since P2X7 receptor is integral in the processing and release of many inflammatory mediators (IL-1β, NFκB, TNFα etc.), the inhibition of this receptor may provide therapeutic benefit in diseases including cancer, tuberculosis, diabetes, asthma, and all of the neurodegenerative diseases. This evidence concerns the gene IL1B and asthma.